|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Piek JM, van Diest PJ and Verheijen RH:
Ovarian carcinogenesis: An alternative hypothesis. Adv Exp Med
Biol. 622:79–87. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Banerjee S and Kaye SB: New strategies in
the treatment of ovarian cancer: Current clinical perspectives and
future potential. Clin Cancer Res. 19:961–968. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nieto MA: Epithelial plasticity: A common
theme in embryonic and cancer cells. Science. 342:12348502013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ghahhari NM and Babashah S: Interplay
between microRNAs and WNT/β-catenin signalling pathway regulates
epithelial-mesenchymal transition in cancer. Eur J Cancer.
51:1638–1649. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vergara D, Merlot B, Lucot JP, Collinet P,
Vinatier D, Fournier I and Salzet M: Epithelial-mesenchymal
transition in ovarian cancer. Cancer Lett. 291:59–66. 2010.
View Article : Google Scholar
|
|
7
|
Rosanò L, Spinella F, Di Castro V, Nicotra
MR, Dedhar S, de Herreros AG, Natali PG and Bagnato A: Endothelin-1
promotes epithelial-to-mesenchymal transition in human ovarian
cancer cells. Cancer Res. 65:11649–11657. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Elloul S, Vaksman O, Stavnes HT, Trope CG,
Davidson B and Reich R: Mesenchymal-to-epithelial transition
determinants as characteristics of ovarian carcinoma effusions.
Clin Exp Metastasis. 27:161–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nuti SV, Mor G, Li P and Yin G: TWIST and
ovarian cancer stem cells: Implications for chemoresistance and
metastasis. Oncotarget. 5:7260–7271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yin G, Alvero AB, Craveiro V, Holmberg JC,
Fu HH, Montagna MK, Yang Y, Chefetz-Menaker I, Nuti S, Rossi M, et
al: Constitutive proteasomal degradation of TWIST-1 in
epithelial-ovarian cancer stem cells impacts differentiation and
metastatic potential. Oncogene. 32:39–49. 2013. View Article : Google Scholar :
|
|
11
|
Kurrey NK, Amit K and Bapat SA: Snail and
Slug are major determinants of ovarian cancer invasiveness at the
transcription level. Gynecol Oncol. 97:155–165. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Prislei S, Martinelli E, Zannoni GF,
Petrillo M, Filippetti F, Mariani M, Mozzetti S, Raspaglio G,
Scambia G and Ferlini C: Role and prognostic significance of the
epithelial-mesenchymal transition factor ZEB2 in ovarian cancer.
Oncotarget. 6:18966–18979. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tian K, Zhang H, Chen X and Hu Z:
Determination of five anthraquinones in medicinal plants by
capillary zone electrophoresis with beta-cyclodextrin addition. J
Chromatogr A. 1123:134–137. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Srinivas G, Babykutty S, Sathiadevan PP
and Srinivas P: Molecular mechanism of emodin action: Transition
from laxative ingredient to an antitumor agent. Med Res Rev.
27:591–608. 2007. View Article : Google Scholar
|
|
16
|
Shrimali D, Shanmugam MK, Kumar AP, Zhang
J, Tan BK, Ahn KS and Sethi G: Targeted abrogation of diverse
signal transduction cascades by emodin for the treatment of
inflammatory disorders and cancer. Cancer Lett. 341:139–149. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hei ZQ, Huang HQ, Tan HM, Liu PQ, Zhao LZ,
Chen SR, Huang WG, Chen FY and Guo FF: Emodin inhibits dietary
induced atherosclerosis by antioxidation and regulation of the
sphingomyelin pathway in rabbits. Chin Med J. 119:868–870.
2006.PubMed/NCBI
|
|
18
|
Li J, Liu P, Mao H, Wanga A and Zhang X:
Emodin sensitizes paclitaxel-resistant human ovarian cancer cells
to paclitaxel-induced apoptosis in vitro. Oncol Rep. 21:1605–1610.
2009.PubMed/NCBI
|
|
19
|
Zhu F, Liu XG and Liang NC: Effect of
emodin and apigenin on invasion of human ovarian carcinoma
HO-8910PM cells in vitro. Ai Zheng. 22:358–362. 2003.In Chinese.
PubMed/NCBI
|
|
20
|
Xue H, Chen Y, Cai X, Zhao L, He A, Guo K
and Zheng X: The combined effect of survivin-targeted shRNA and
emodin on the proliferation and invasion of ovarian cancer cells.
Anticancer Drugs. 24:937–944. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pooja T and Karunagaran D: Emodin
suppresses Wnt signaling in human colorectal cancer cells SW480 and
SW620. Eur J Pharmacol. 742:55–64. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thacker PC and Karunagaran D: Curcumin and
emodin down-regulate TGF-β signaling pathway in human cervical
cancer cells. PLoS One. 10:e01200452015. View Article : Google Scholar
|
|
23
|
Way TD, Huang JT, Chou CH, Huang CH, Yang
MH and Ho CT: Emodin represses TWIST1-induced
epithelial-mesenchymal transitions in head and neck squamous cell
carcinoma cells by inhibiting the β-catenin and Akt pathways. Eur J
Cancer. 50:366–378. 2014. View Article : Google Scholar
|
|
24
|
Davidowitz RA, Selfors LM, Iwanicki MP,
Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE,
et al: Mesenchymal gene program-expressing ovarian cancer spheroids
exhibit enhanced mesothelial clearance. J Clin Invest.
124:2611–2625. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Anastas JN and Moon RT: WNT signalling
pathways as therapeutic targets in cancer. Nat Rev Cancer.
13:11–26. 2013. View
Article : Google Scholar
|
|
27
|
Arend RC, Londoño-Joshi AI, Straughn JM Jr
and Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: A
review. Gynecol Oncol. 131:772–779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rao TP and Kühl M: An updated overview on
Wnt signaling pathways: A prelude for more. Circ Res.
106:1798–1806. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sánchez-Tilló E, de Barrios O, Siles L,
Cuatrecasas M, Castells A and Postigo A: β-catenin/TCF4 complex
induces the epithelial-to-mesenchymal transition (EMT)-activator
ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA.
108:19204–19209. 2011. View Article : Google Scholar
|
|
30
|
Wu K, Fan J, Zhang L, Ning Z, Zeng J, Zhou
J, Li L, Chen Y, Zhang T, Wang X, et al: PI3K/Akt to
GSK3β/β-catenin signaling cascade coordinates cell colonization for
bladder cancer bone metastasis through regulating ZEB1
transcription. Cell Signal. 24:2273–2282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moreno-Bueno G, Portillo F and Cano A:
Transcriptional regulation of cell polarity in EMT and cancer.
Oncogene. 27:6958–6969. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Khan MA, Chen HC, Zhang D and Fu J: Twist:
A molecular target in cancer therapeutics. Tumour Biol.
34:2497–2506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: An alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schmalhofer O, Brabletz S and Brabletz T:
E-cadherin, beta-catenin, and ZEB1 in malignant progression of
cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen D, Wang J, Zhang Y, Chen J, Yang C,
Cao W, Zhang H, Liu Y and Dou J: Effect of down-regulated
transcriptional repressor ZEB1 on the epithelial-mesenchymal
transition of ovarian cancer cells. Int J Gynecol Cancer.
23:1357–1366. 2013. View Article : Google Scholar : PubMed/NCBI
|
